Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy

Hypertension

Volumn 61, Issue 2, 2013, Pages 327-332

  Gladysheva, Inna P ^a   Wang, Dong ^a   McNamee, Rachel A ^b   Houng, Aiilyan K ^a   Mohamad, Almois A ^b   Fan, T Michael ^a   Reed, Guy L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

corin; dilated cardiomyopathy; heart failure; natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CORIN; CYCLIC GMP; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; EX VIVO STUDY; GENE OVEREXPRESSION; GENE TARGETING; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART SIZE; HISTOPATHOLOGY; IN VIVO STUDY; LUNG ALVEOLUS; LUNG CONGESTION; LUNG FLUID; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; FIBROSIS; HEART; HEART FAILURE; HYPERTENSION; MICE; MICE, TRANSGENIC; MYOCARDIUM; SERINE ENDOPEPTIDASES;

EID: 84873058628     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.193631     Document Type: Article

References (44)

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-1955.
3. Ibebuogu UN, Gladysheva IP, Reed GL. Is heart failure due to impaired cleavage and activation of atrial natriuretic peptide? J Am Coll Cardiol. 2009;53:A467-A468.
4. Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail. 2011;4:114-120.
5. Dong N, Chen S, Yang J, He L, Liu P, Zheng D, Li L, Zhou Y, Ruan C, Plow E, Wu Q. Plasma soluble corin in patients with heart failure. Circ Heart Fail. 2010;3:207-211.
6. Dries DL, Victor RG, Rame JE, Cooper RS, Wu X, Zhu X, Leonard D, Ho SI, Wu Q, Post W, Drazner MH. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112:2403-2410. (Pubitemid 41504489)
7. Hooper JD, Scarman AL, Clarke BE, Normyle JF, Antalis TM. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem. 2000;267:6931-6937.
8. Gladysheva IP, Robinson BR, Houng AK, Kováts T, King SM. Corin is co-expressed with pro-ANP and localized on the cardiomyocyte surface in both zymogen and catalytically active forms. J Mol Cell Cardiol. 2008;44:131-142.
9. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000;97:8525-8529. (Pubitemid 30639706)
10. Wang W, Liao X, Fukuda K, Knappe S, Wu F, Dries DL, Qin J, Wu Q. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res. 2008;103:502-508.
11. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC Jr, Ikeda Y. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem. 2011;57:864-873.
12. Peng J, Jiang J, Wang W, Qi X, Sun XL, Wu Q. Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. Biochem Biophys Res Commun. 2011;411:593-598.
13. Ichiki T, Huntley BK, Heublein DM, Sandberg SM, McKie PM, Martin FL, Jougasaki M, Burnett JC Jr. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem. 2011;57:40-47.
14. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, Koshkina EV, Krasnoselsky MI, Katrukha AG. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem. 2010;56:1166-1176.
15. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-2159.
16. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72. (Pubitemid 43228238)
17. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816. (Pubitemid 43958474)
18. Patten RD, Hall-Porter MR. Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail. 2009;2:138-144.
19. Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest. 1998;101:2415-2426. (Pubitemid 28270436)
20. Mor-Avi V, Korcarz C, Fentzke RC, Lin H, Leiden JM, Lang RM. Quantitative evaluation of left ventricular function in a TransgenicMouse model of dilated cardiomyopathy with 2-dimensional contrast echocardiography. J Am Soc Echocardiogr. 1999;12:209-214. (Pubitemid 29128252)
21. Fentzke RC, Korcarz CE, Shroff SG, Lin H, Leiden JM, Lang RM. The left ventricular stress-velocity relation in transgenic mice expressing a dominant negative CREB transgene in the heart. J Am Soc Echocardiogr. 2001;14:209-218. (Pubitemid 33791851)
22. Zhu W, Saba S. Cardiac electrophysiologic abnormalities in the CREBA133 transgenic mouse model of idiopathic dilated cardiomyopathy. J Cardiovasc Electrophysiol. 2003;14:982-989. (Pubitemid 37115163)
23. Huggins GS, Lepore JJ, Greytak S, Patten R, McNamee R, Aronovitz M, Wang PJ, Reed GL. The CREB leucine zipper regulates CREB phosphorylation, cardiomyopathy, and lethality in a transgenic model of heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H1877-H1882. (Pubitemid 47367238)
24. Shrestha K, Troughton RW, Borowski AG, Yandle TG, Richards AM, Klein AL, Tang WH. Plasma corin levels provide minimal prognostic utility incremental to natriuretic peptides in chronic systolic heart failure. J Card Fail. 2010;16:621-627.
25. Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kääb S, Kreuzer E, Steinbeck G, Mansmann U, Poustka A, Nabauer M, Sültmann H. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol. 2006;48:1610-1617. (Pubitemid 44528176)
26. Tran KL, Lu X, Lei M, Feng Q, Wu Q. Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium. Am J Physiol Heart Circ Physiol. 2004;287:H1625-H1631. (Pubitemid 39313267)
27. Langenickel TH, Pagel I, Buttgereit J, Tenner K, Lindner M, Dietz R, Willenbrock R, Bader M. Rat corin gene: molecular cloning and reduced expression in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004;287:H1516-H1521. (Pubitemid 39313254)
28. Chen S, Sen S, Young D, Wang W, Moravec CS, Wu Q. Protease corin expression and activity in failing hearts. Am J Physiol Heart Circ Physiol. 2010;299:H1687-H1692.
29. Pan J, Hinzmann B, Yan W, Wu F, Morser J, Wu Q. Genomic structures of the human and murine corin genes and functional GATA elements in their promoters. J Biol Chem. 2002;277:38390-38398. (Pubitemid 35154695)
30. Chan JC, Knudson O, Wu F, Morser J, Dole WP, Wu Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA. 2005;102:785-790. (Pubitemid 40282743)
31. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147. (Pubitemid 16016312)
32. Wang W, Shen J, Cui Y, Jiang J, Chen S, Peng J, Wu Q. Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. Kidney Int. 2012;82:26-33.
33. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005;69:283-290. (Pubitemid 40410182)
34. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787-1793.
35. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AH, Dries DL. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail. 2009;2:541-548.
36. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355-360.
37. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
38. Vollmar AM. The role of atrial natriuretic peptide in the immune system. Peptides. 2005;26:1086-1094. (Pubitemid 40725379)
39. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69:318-328. (Pubitemid 43098788)
40. Yasuno S, Usami S, Kuwahara K, Nakanishi M, Arai Y, Kinoshita H, Nakagawa Y, Fujiwara M, Murakami M, Ueshima K, Harada M, Nakao K. Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death. Am J Physiol Heart Circ Physiol. 2009;296:H1804-H1810.
41. Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F, Perry G. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension. 2004;44:746-750. (Pubitemid 39435248)
42. Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol. 2001;79:723-729. (Pubitemid 32745039)
43. Zannad F, Pitt B. Biomarkers of extracellular matrix turnover. Heart Fail Clin. 2009;5:589-599.
44. Buckley CL, Stokes AJ. Corin-deficient W-sh mice poorly tolerate increased cardiac afterload. Regul Pept. 2011;172:44-50.